Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.
He was trained and received his doctorate in Italy from the University School of Medicine in Turin. After his residency, he worked for another 4 years in Turin as a Consultant Oncologist. From 2010 to 2017 he further sharpened his interest in thoracic malignancies in the UK. First at the United Lincolnshire Hospital NHS Trust and later at the University Hospital Bristol, Dr. Addeo also took on the role as senior lecturer in Medical Oncology. As an active member of the NCRI Mesothelioma Working Group, he has also participated in several national and international NCRI drug studies. Dr. Addeo’s research continues to focus on drug development and translational aspects of precision medicine, immunotherapy and side effects, particularly in small and non-smal cell lung cancer (NSCLC) as well as melanoma.
During his time in the UK, Dr. Addeo developed further research interests in liquid biopsies, ctDNA analysis, and tumor mutation burden (TMB) in blood samples. For his research activities in this field he received a grant for a research proposal, which is still ongoing.
In September 2017, Dr. Addeo moved to Geneva, where he received the post of medical oncologist with a primary responsibility for Thoracic Malignancies.
Solange Peters, MD, PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President-elect ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group.
She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.
Professor Peters is currently in charge of teaching and patient care in the area of Thoracic Malignancies in the department of oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Dr. Hanahan at the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Professor Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy.
Professor Peters’ current research projects are focused on multimodality stage III NSCLC treatment strategies, immunotherapy in limited small cell lung cancer and advanced thymic malignancies, advanced NSCLC, ALK inhibitors, HER2 inhibitors, as well as immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre, focused on phase I predictive biomarkers and thoracic malignancies immunotherapy, and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator of the European Thoracic Oncology Platform (ETOP).
|8.30 – 9.00||Registration and Coffee|
|9.00||Welcome by Chairs||S. Peters & A. Addeo|
|9.15||Treatment sequence in non-oncogene addicted NSCLC||R. Stahel|
|9.45||Are all immunotherapies alike?||G. Banna|
|10.15||Importance and implications of biomarkers in NSCLC: is TMB ready for prime time?||U. Malapelle|
|10.45||Open Discussion & Coffee Break|
|11.30||State of the art in SCLC: moving towards new treatment standards||S. Liu|
|12.00||DEBATE: This house believes PCI should be offered in ED SCLC||F. Caparrotti & M. Pless|
|14.00||State of the art in ALK-rearranged NSCLC: which TKI inhibitors will I use in my clinical practice?||A. Curioni|
|14.30||DEBATE: State of the art in EGFR+ NSCLC: is there still room for second generation TKIs?||C. Comins & S. Rothschild|
|15.10||BRAF, ROS1, RET, MET, NTRK: are these all actionable mutations in NSCLC?||S. Patel|
|15.40||Open Discussion & Coffee Break|
|16.15||Oligometastatic disease in NSCLC: is there a new treatment paradigm?||J. Bauml|
|16.45||Importance and impact of Quality of Life data in clinical trials||M. Di Maio|
|17.15||Final Questions and Wrap Up|
Université de Genève / Centre Médical Universitaire
Rue Michel-Servet 1
1206 Genève, Switzerland
We are excited to have @UmbertoMalapel1 representing the pathologists at the #LungSummit. Join live online on 3rd of May at 10.15am CET to learn more about "Importance and implications of biomarkers in NSCLC: is TMB ready for prime time?" #lungcancer #LCSM
I’ll second that! @BTOGORG #LCSM
Great discussion @BTOGORG Board of Trustees, AGM & Steering Committee meetings to develop the BTOG brand. Lots of developments planned with @DrSanjayPopat and the rest of the SC. Who knew the website added value? Let’s make it the “go to” for #lungcancer #mesothelioma #LCSM
“His aggressive lung cancer, now stage four terminal, was detected by a civilian doctor after the tumor had metastasized.” #lcsm
NC Geen Beret’s missed cancer diagnosis leads to bill, march in DC https://t.co/ujlPYDaLAQ @FOX46News @WhistleblowerLF @NatalieKhawam
Are you interested to sponsor our event?
Please contact us at firstname.lastname@example.org